Advertisement
UK markets open in 55 minutes
  • NIKKEI 225

    38,790.32
    -132.68 (-0.34%)
     
  • HANG SENG

    18,469.27
    +66.27 (+0.36%)
     
  • CRUDE OIL

    73.38
    -0.84 (-1.13%)
     
  • GOLD FUTURES

    2,367.60
    -1.70 (-0.07%)
     
  • DOW

    38,571.03
    -115.27 (-0.30%)
     
  • Bitcoin GBP

    53,828.95
    +170.14 (+0.32%)
     
  • CMC Crypto 200

    1,444.98
    -2.17 (-0.15%)
     
  • NASDAQ Composite

    16,828.67
    +93.67 (+0.56%)
     
  • UK FTSE All Share

    4,517.03
    -0.05 (-0.00%)
     

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd.

HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time).

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ®

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com